Physician profile

Allison H Doyle

Family Medicine · Meridian, MS

NPI 1063692770

$1,824.71

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$613.20
Food and Beverage$160.71

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $613.20 2023-2024 Cardiomems
Novo Nordisk INC $418.44 2019-2023 Wegovy
Astrazeneca Pharmaceuticals LP $267.84 2019-2020
Allergan, INC. $147.03 2019
Sunovion Pharmaceuticals INC. $143.48 2019
Boehringer Ingelheim Pharmaceuticals, INC. $124.56 2024 Jardiance
Merz North America, INC. $97.61 2021-2022
Novartis Pharmaceuticals Corporation $12.55 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Allison H Doyle

$1,824.71

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbott Laboratories

https://glasscript.com/doctor/184692/allison-h-doyle

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.